SuperworthAllogene Therapeutics shares outstanding ALLO
Diluted shares outstanding, averaged over each quarter, from 2018.
- Latest quarter, to Jun 30, 2026
- 328.9M
- On a year earlier
- +50.2%
- more shares
Allogene Therapeutics had 328.9M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 50.2% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 226M | +7% |
| FY2024 | 210.6M | +25% |
| FY2023 | 168.3M | +17% |
| FY2022 | 144.1M | +4% |
| FY2021 | 139.2M | +7% |
| FY2020 | 129.7M | +24% |
| FY2019 | 104.8M | +28% |
| FY2018 | 82.1M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 328.9M | +50% | |
| Q1 FY26 | 240.3M | +12% | |
| Q4 FY25 | 226M | +7% | |
| Q3 FY25 | 222M | +6% | |
| Q2 FY25 | 218.9M | +15% | |
| Q1 FY25 | 215.4M | +27% | |
| Q4 FY24 | 210.6M | +25% | |
| Q3 FY24 | 209.2M | +25% | |
| Q2 FY24 | 190M | +29% | |
| Q1 FY24 | 169.1M | +17% | |
| Q4 FY23 | 168.3M | +17% | |
| Q3 FY23 | 167.6M | +17% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Allogene Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.